Alkem Foundation, IIT Bombay to Set Up Advanced Research Centre

05 Nov 2025 CW Team

Under this partnership, Alkem Foundation will fund the creation of the Alkem Centre for Advanced Research and Development of Applied Immuno-Therapeutics and Regenerative Medicines within the IIT Bombay campus. The foundation will contribute around 20–25 per cent of its cumulative CSR obligations over seven years towards this project.

The initiative marks India’s first industry–academia collaboration, initiated through the CSR route, to promote advanced research in these complex therapeutic areas. It will combine Alkem’s experience in developing pharmaceutical solutions with IIT Bombay’s expertise in biomedical engineering, biosciences, and translational research to create an innovation-driven ecosystem.

The centre aims to build a holistic platform for research, innovation, and skill development in high-precision and underserved therapy areas, bridging gaps in infrastructure, talent, and translational capability. It will also align with IIT Bombay’s multidisciplinary healthcare approach that integrates biology, engineering, and data science to advance human health.

Future research will explore frontier domains such as gene editing, biomaterials, and delivery technologies for immuno-therapeutics and regenerative medicine. The centre will serve as a hub for clinician-scientists and biotech entrepreneurs, supported by IIT Bombay faculty, Alkem mentors, and global experts from leading universities.

Madhurima Singh, Executive Director and Chairperson, CSR and Sustainability Committee, Alkem, said, “We believe in going beyond business to support R&D in areas of significant medical need. Our partnership with IIT Bombay reflects a shared commitment to fostering innovation and developing advanced, affordable treatments that can enhance both lifespan and quality of life.”

Prof. Shireesh B. Kedare, Director, IIT Bombay, added, “This collaboration will accelerate translation of cutting-edge research into real-world healthcare impact, helping India achieve self-reliance in biomedical innovation.”

Mumbai, November 3, 2025 — Alkem Foundation, the Corporate Social Responsibility (CSR) arm of Alkem Laboratories, has announced a strategic collaboration with the Indian Institute of Technology Bombay (IIT Bombay) to establish a first-of-its-kind research centre in India dedicated to immuno-therapeutics and regenerative medicines. Under this partnership, Alkem Foundation will fund the creation of the Alkem Centre for Advanced Research and Development of Applied Immuno-Therapeutics and Regenerative Medicines within the IIT Bombay campus. The foundation will contribute around 20–25 per cent of its cumulative CSR obligations over seven years towards this project. The initiative marks India’s first industry–academia collaboration, initiated through the CSR route, to promote advanced research in these complex therapeutic areas. It will combine Alkem’s experience in developing pharmaceutical solutions with IIT Bombay’s expertise in biomedical engineering, biosciences, and translational research to create an innovation-driven ecosystem. The centre aims to build a holistic platform for research, innovation, and skill development in high-precision and underserved therapy areas, bridging gaps in infrastructure, talent, and translational capability. It will also align with IIT Bombay’s multidisciplinary healthcare approach that integrates biology, engineering, and data science to advance human health. Future research will explore frontier domains such as gene editing, biomaterials, and delivery technologies for immuno-therapeutics and regenerative medicine. The centre will serve as a hub for clinician-scientists and biotech entrepreneurs, supported by IIT Bombay faculty, Alkem mentors, and global experts from leading universities. Madhurima Singh, Executive Director and Chairperson, CSR and Sustainability Committee, Alkem, said, “We believe in going beyond business to support R&D in areas of significant medical need. Our partnership with IIT Bombay reflects a shared commitment to fostering innovation and developing advanced, affordable treatments that can enhance both lifespan and quality of life.” Prof. Shireesh B. Kedare, Director, IIT Bombay, added, “This collaboration will accelerate translation of cutting-edge research into real-world healthcare impact, helping India achieve self-reliance in biomedical innovation.”

Infrastructure Urban

12 Nov 2025

Lemon Tree Opens Sixth Hotel in Kerala

Lemon Tree Hotels, India’s fastest-growing mid-scale and premium hotel chain, has announced the opening of its latest managed property — Lemon Tree Premier, Thiruvananthapuram.This marks the brand’s sixth property in Kerala and further strengthens its growing footprint across southern India.Strategically located in the heart of the state capital, Lemon Tree Premier, Thiruvananthapuram offers easy access to major business districts, government offices, and cultural landmarks. The city — known for its rich heritage, iconic Padmanabhaswamy Temple, scenic beaches such as Kovalam, and growi..

Infrastructure Urban

12 Nov 2025

NALCO Reports Record Q2 & H1 FY26 Performance

National Aluminium Company (NALCO), a Navratna CPSE under the Ministry of Mines, Government of India, has reported its best-ever quarterly and half-yearly physical and financial performance in FY 2025–26.For the quarter ended September 2025 (Q2 FY26), NALCO’s net profit surged 35 per cent year-on-year to Rs 14.33 billion, compared to Rs 10.62 billion in the same period last year. The company’s total income from operations rose 7.2 per cent to Rs 42.92 billion, reflecting robust operational performance and supportive market conditions.For the first half of FY26, NALCO’s net profit jumpe..

Infrastructure Urban

12 Nov 2025

SDHI to Build Six Tankers for Norway’s Stenersen

Swan Defence and Heavy Industries (SDHI), India’s largest shipbuilding and heavy fabrication company, has signed a Letter of Intent (LoI) with Norwegian ship owner Rederiet Stenersen AS for the construction of six IMO Type II chemical tankers, each with a capacity of 18,000 DWT.Valued at approximately $220 million, the LoI represents a landmark achievement for India’s shipbuilding exports, with an option to build an additional six vessels under the same class. The ships will be built at SDHI’s state-of-the-art shipyard in Pipavav, Gujarat, designed by Marinform AS, Norway, and classed by..